Your shopping cart is empty.
EP2047867 - Bibliographic data
Last update | 06/20/2023 |
---|---|
Legal status | Invention expirée |
Origin | Européen |
(73)Owner |
APEIRON BIOLOGICS AG Campus-Vienna-Biocenter 5 1030 Wien Autriche |
(72)Inventors |
Crackower, Michael A. St. Lazare, Quebec J7T 3J8 Canada |
Penninger, Joseph M 1130 Vienna Autriche |
|
(74)Agent |
Mail recipient CABINET CURAU "Le Rose de France" 17, boulevard de Suisse PO Box 54 98000 MONACO Principauté de Monaco |
(21)Application number | EP08019249.5 |
(22)Application date | 06/19/2003 |
(11)Publication number | EP2047867 |
Grant date | 05/22/2013 |
(54)Invention title | ACE2 activation for treatment of heart, lung and kidney disease and hypertension |
(51)International classification | A61K 48/00, C12N 9/64, A61K 38/48, C12N 9/64, A61K 38/48 |
International classification (before reform) | None |
Claimed priority |
(31) Number: 389709 P (32) Date: 06/19/2002 (33) Country: US |
Initial application | None |
Divisional application | None |
Expected annuity | None |
Last annuity | Annuity: 20 - Amount: 430€ - Payment date 06/21/2022 |
Publication | BREVETS D'INVENTION DESIGNANT MC DELIVRES PAR l'OEB - bulletin 2013/2, of 06/30/2013 |
History | Publication de la délivrance du brevet européen - Legal date 05/22/2013 |
Constitution de mandataire pour un dossier - Legal date 08/27/2013 | |
Constitution de mandataire pour un dossier - Legal date 03/03/2016 | |
Expiration de l'invention - Legal date 06/20/2023 |